Aerow hits the mark for 4D Molecular
An early success with its cystic fibrosis gene therapy brings the company up.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Arrowhead delivers in the lung
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.